

Enhanced reporting capabilities

Pris^m now offers the industry's first electronic messaging system for identification and tracking of safety trends, providing researchers with early alerts of potentially significant safety developments. Developed by **Nextrials Inc.**, Prism's enhanced safety features give research professionals the ability to set threshold tolerance levels for investigational studies of biopharmaceuticals and medical devices. Researchers can then monitor these thresholds in real time across multiple test sites and multiple studies, receiving electronic alerts when data trends point to potential safety concerns.

The new system solves two pressing problems for the industry by providing immediate access to data obtained across multiple project sites and studies while helping minimize public and financial risks when clinical data shows safety concerns.

"This new capability is in direct response to the industry's increasing focus on safety," says James

Rogers, co-founder and CEO, Nextrials (nextrials.com). "Researchers have traditionally reviewed safety data on a periodic basis by analyzing data that is weeks or even months out-of-date. This delay exposes sponsors and patients to unnecessary risks. Prism's safety alert system provides life sciences companies with an early warning system for clinical trials that increases patient safety."

Prism's advanced data mining capability spots and analyzes multi-project safety trends, even in cases where the overall clinical trial remains below threshold levels, and electronically sends notification to researchers. This increases the ability to conduct significant, complex clinical research in a safe and cost-effective environment.

In addition, Nextrials added international reporting capabilities to Prism, enabling pharmaceutical, biotechnology, and medical device companies to more quickly comply with regulations for safety reporting in countries around the globe.

Nextrials offers products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism has been used at more than 200 research sites to streamline the initiation and management of clinical trials.